The role of DARPP-32 in the actions of drugs of abuse

Neuropharmacology

Volumn 47, Issue SUPPL. 1, 2004, Pages 14-23

  Nairn, Angus C ^a,b   Svenningsson, Per ^a   Nishi, Akinori ^a,c   Fisone, Gilberto ^a,d   Girault, Jean Antoine ^e   Greengard, Paul ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KAROLINSKA INSTITUTE   (Sweden)

^e INSERM   (France)

Author keywords

Amphetamine; Cocaine; Dopamine; Nicotine; Opiate; Phosphorylation; Protein; Protein phosphatase; Serotonin

Indexed keywords

AMPHETAMINE; COCAINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; DEXAMPHETAMINE; DOPAMINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GLUTAMIC ACID; LYSERGIDE; MU OPIATE RECEPTOR AGONIST; NEUROPEPTIDE; NEUROTRANSMITTER; OPIATE; PHOSPHOPROTEIN; PHOSPHOPROTEIN DARPP 32; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN SERINE THREONINE KINASE; SEROTONIN; THREONINE;

BEHAVIOR; BRAIN REGION; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG MECHANISM; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; HUMAN; NEOSTRIATUM; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 4644272703     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.05.010     Document Type: Article

References (79)

1. Aizman O., Brismar H., Uhlen P., Zettergren E., Levey A.I., Forssberg H., Greengard P., Aperia A. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat. Neurosci. 3:2000;226-230
2. Anderson K.D., Reiner A. Immunohistochemical localization of DARPP-32 in striatal projection neurons and striatal interneurons: implications for the localization of D1-like dopamine receptors on different types of striatal neurons. Brain Res. 568:1991;235-243
3. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152
4. Beckstead R.M., Cruz C.J. Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat. Neuroscience. 19:1985;147-158
5. 2+ connection in dopamine signaling. Trends Pharmacol. Sci. 24:2003;486-492
6. Bibb J.A., Snyder G.L., Nishi A., Yan Z., Meijer L., Fienberg A.A., Tsai L.H., Kwon Y.T., Girault J.A., Czernik A.J., Huganir R.L., Hemmings H.C. Jr., Nairn A.C., Greengard P. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 402:1999;669-671
7. Bibb J.A., Chen J., Taylor J.R., Svenningsson P., Nishi A., Snyder G.L., Yan Z., Sagawa Z.K., Ouimet C.C., Nairn A.C., Nestler E.J., Greengard P. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature. 410:2001;376-380
8. Calabresi P., Gubellini P., Centonze D., Picconi B., Bernardi G., Chergui K., Svenningsson P., Fienberg A.A., Greengard P. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J. Neurosci. 20:2000;8443-8451
9. Carboni E., Imperato A., Perezzani L., Di Chiara G. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience. 28:(3):1989;653-661
10. Chiamulera C., Epping-Jordan M.P., Zocchi A., Marcon C., Cottiny C., Tacconi S., Corsi M., Orzi F., Conquet F. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 4:2001;873-874
11. da Cruze Silva E.F., Fox C.A., Ouimet C.C., Gustafson E., Watson S.J., Greengard P. Differential expression of protein phosphatase 1 isoforms in mammalian brain. J. Neurosci. 15:1995;3375-3389
12. Desdouits F., Cohen D., Nairn A.C., Greengard P., Girault J.A. Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase I in vitro and in vivo. J. Biol. Chem. 270:1995a;8772-8778
13. 34 by calcineurin. Proc. Natl. Acad. Sci. USA. 92:1995b;2682-2685
14. Ferre S., Karcz-Kubicha M., Hope B.T., Popoli P., Burgueno J., Gutierrez M.A., Casado V., Fuxe K., Goldberg S.R., Lluis C., Franco R., Ciruela F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. USA. 99:2002;11940-11945
15. Fienberg A.A., Greengard P. The DARPP-32 knockout mouse. Brain Res. Brain Res. Rev. 31:2000;313-319
16. Fienberg A.A., Hiroi N., Mermelstein P.G., Song W., Snyder G.L., Nishi A., Cheramy A., O'Callaghan J.P., Miller D.B., Cole D.G., Corbett R., Haile C.N., Cooper D.C., Onn S.P., Grace A.A., Ouimet C.C., White F.J., Hyman S.E., Surmeier D.J., Girault J., Nestler E.J., Greengard P. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science. 281:1998;838-842
17. Flores-Hernandez J., Hernandez S., Snyder G.L., Yan Z., Fienberg A.A., Moss S.J., Greengard P., Surmeier D.J. D(1) dopamine receptor activation reduces GABA(A) receptor currents in neostriatal neurons through a PKA/DARPP-32/PP1 signaling cascade. J. Neurophysiol. 83:2000;2996-3004
18. Flores-Hernandez J., Cepeda C., Hernandez-Echeagaray E., Calvert C.R., Jokel E.S., Fienberg A.A., Greengard P., Levine M.S. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J. Neurophysiol. 88:2002;3010-3020
19. Georges F., Stinus L., Bloch B., Le Moine C. Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. Eur. J. Neurosci. 11:1999;481-490
20. Gerfen C.R., Young W.S. III. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 460:1988;161-167
21. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J. Jr., Sibley D.R. D1 and D2 receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432
22. Girault J.A., Hemmings H.C. Jr., Williams K.R., Nairn A.C., Greengard P. Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II. J. Biol. Chem. 264:1989;21748-21759
23. Gong S., Zheng C., Doughty M.L., Losos K., Didkovsky N., Schambra U.B., Nowak N.J., Joyner A., Leblanc G., Hatten M.E., Heintz N. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature. 425:2003;917-925
24. Greengard P. The neurobiology of slow synaptic transmission. Science. 294:2001;1024-1030
25. Greengard P., Allen P.B., Nairn A.C. Beyond the dopamine receptor: the DARPP 32/protein phosphatase-1 cascade. Neuron. 23:1999;435-447
26. Hagiwara M., Alberts A., Brindle P., Meinkoth J., Feramisco J., Deng T., Karin M., Shenolikar S., Montminy M. Transcriptional attenuation following cAMP induction requires PP-1-mediated dephosphorylation of CREB. Cell. 70:1992;105-113
27. Halpain S., Girault J.-A., Greengard P. Activation of NMDA receptors induced dephosphorylation of DARPP-32 in rat striatal slices. Nature. 343:1990;369-372
28. Hamada, M., Higashi, H., Nairn, A.C., Greengard, P., Nishi, A., 2004. Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons. J. Neurochem. (in press).
29. Hemmings H.C. Jr., Greengard P., Tung H.Y., Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 310:1984;503-505
30. Heyser C.J., Fienberg A.A., Greengard P., Gold L.H. DARPP-32 knockout mice exhibit impaired reversal learning in a discriminated operant task. Brain Res. 867:2000;122-130
31. Hiroi N., Fienberg A.A., Haile C.N., Alburges M., Hanson G.R., Greengard P., Nestler E.J. Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice. Eur. J. Neurosci. 11:1999;1114-1118
32. Hyman S.E., Malenka R.C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat. Rev. Neurosci. 2:2001;695-703
33. Kawaguchi Y., Wilson C.J., Emson P.C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 10:1990;3421-3438
34. Laviolette S.R., van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. 5:2004;55-65
35. 2a receptor. Nature. 388:1997;674-678
36. Lindskog M., Svenningsson P., Fredholm B.B., Greengard P., Fisone G. Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience. 88:1999a;1005-1008
37. Lindskog M., Svenningsson P., Fredholm B., Greengard P., Fisone G. Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. Eur. J. Neurosci. 11:1999b;2182-2186
38. Lindskog M., Svenningsson P., Pozzi L., Kim Y., Fienberg A.A., Bibb J.A., Fredholm B.B., Nairn A.C., Greengard P., Fisone G. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature. 418:2002;774-778
39. Liu F.C., Graybiel A.M. Spatiotemporal dynamics of CREB phosphorylation: transient versus sustained phosphorylation in the developing striatum. Neuron. 17:1996;1133-1144
40. Liu F., Ma X.H., Ule J., Bibb J.A., Nishi A., DeMaggio A.J., Yan Z., Nairn A.C., Greengard P. Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors. Proc. Natl. Acad. Sci. USA. 98:2001;11062-11068
41. Liu F., Virshup D.M., Nairn A.C., Greengard P. Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors. J. Biol. Chem. 277:2002;43393-43399
42. Lovinger D.M., White G., Weight F.F. Ethanol inhibits NMDA-activated ion currents in hippocampal neurons. Science. 243:1989;1721-1724
43. Maldve R.E., Zhang T.A., Ferrani-Kile K., Schreiber S.S., Lippmann M.J., Snyder G.L., Fienberg A.A., Leslie S.W., Gonzales R.A., Morrisett R.A. DARPP-32 and regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens. Nat. Neurosci. 5:2002;641-648
44. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2:2001;119-128
45. Nishi A., Snyder G.L., Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17:1997;8147-8155
46. Nishi A., Bibb J.A., Snyder G.L., Higashi H., Nairn A.C., Greengard P. Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. USA. 97:2000;12840-12845
47. Nishi A., Bibb J.A., Matsuyama S., Hamada M., Higashi H., Nairn A.C., Greengard P. Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J. Neurochem. 81:2002;832-841
48. 2A receptor signaling. Proc. Natl. Acad. Sci. USA. 100:2003;1322-1327
49. Nomikos G.G., Schilstrom B., Hildebrand B.E., Panagis G., Grenhoff J., Svensson T.H. Role of α7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav. Brain Res. 113:2000;97-103
50. Ouimet C.C., Greengard P. Distribution of DARPP-32 in the basal ganglia: an electron microscopic study. J. Neurocytol. 19:1990;39-52
51. Ouimet C.C., Miller P.E., Hemmings H.C. Jr., Walaas S.I., Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J. Neurosci. 4:1984;111-124
52. Ouimet C.C., Langley-Gullion K.C., Greengard P. Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res. 808:1998;8-12
53. Parsons L.H., Koob G.F., Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J. Pharmacol. Exp. Ther. 274:1995;1182-1191
54. Picciotto M.R. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol. Sci. 24:2003;493-499
55. Ramirez-Latorre J., Crabtree G., Turner J., Role L. Molecular composition and biophysical characteristics of nicotine receptors. Arneric S.P., Brioni J.D. Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities. 1999;43-64 Wiley-Liss Inc, New York
56. Risinger F.O., Freeman P.A., Greengard P., Fienberg A.A. Motivational effects of ethanol in DARPP-32 knock-out mice. J. Neurosci. 21:2001;340-348
57. Role L.W., Berg D.K. Nicotinic receptors in the development and modulation of CNS synapses. Neuron. 16:1996;1077-1085
58. Sacaan A.I., Bymaster F.P., Schoepp D.D. Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. J. Neurochem. 59:1992;245-251
59. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology. 38:1999;1431-1476
60. Shoffelmeer A.N., Hansen H.A., Stoof J.C., Mulder A.H. Blockade of D-2 dopamine receptors strongly enhances the potency of enkephalins to inhibit dopamine-sensitive adenylate cyclase in rat neostriatum: involvement of delta- and mu-opioid receptors. J. Neurosci. 6:1986;2235-2239
61. Snyder G.L., Fienberg A.A., Huganir R.L., Greengard P. A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J. Neurosci. 18:1998;10297-10303
62. Stoof J.C., Kebabian J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature. 294:1981;366-368
63. Surmeier D.J., Son W.J., Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16:1996;6579-6591
64. 2A receptors. Prog. Neurobiol. 59:1999;355-396
65. 2A receptors. Proc. Natl. Acad. Sci. USA. 97:2000a;1856-1860
66. Svenningsson P., Fienberg A.A., Allen P.B., LeMoine C., Lindskog M., Fisone G., Greengard P., Fredholm B.B. Dopamine D1 receptor-induced gene transcription is modulated by DARPP-32. J. Neurochem. 75:2000b;248-257
67. Svenningsson P., Tzavara E.T., Liu F., Fienberg A.A., Nomikos G.G., Greengard P. DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc. Natl. Acad. Sci. USA. 99:2002;3188-3193
68. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science. 302:2003;1412-1415
69. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., Greengard P. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 44:2004;269-296
70. Tallaksen-Greene S.J., Kaatz K.W., Romano C., Albin R.L. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Res. 780:1998;210-217
71. Testa C.M., Friberg I.K., Weiss S.W., Standaert D.G. Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia. J. Comp. Neurol. 390:1998;5-19
72. Walaas S.I., Aswad D.W., Greengard P. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature. 301:1983;69-71
73. Wang J.Q., McGinty J.F. Metabotropic glutamate receptor agonist increases neuropeptide mRNA expression in rat striatum. Brain Res. Mol. Brain. Res. 54:1998;262-269
74. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 20:1997;92-98
75. Yan Z., Hsieh-Wilson L., Feng J., Tomizawa K., Allen P.B., Fienberg A.A., Nairn A.C., Greengard P. Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat. Neurosci. 2:1999a;13-17
76. Yan Z., Feng J., Fienberg A.A., Greengard P. D2 dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proc. Natl. Acad. Sci. USA. 96:1999b;11607-11612
77. Yoshida M., Precht W. Monosynaptic inhibition of neurons of the substantia nigra by caudato-nigral fibers. Brain Res. 32:1971;225-228
78. Zachariou V., Benoit-Marand M., Allen P.B., Ingrassia P., Fienberg A.A., Gonon F., Greengard P., Picciotto M.R. Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP 32 or inhibitor 1. Biol. Psychiatr. 51:2002;612-620
79. Zoli M., Moretti M., Zanardi A., McIntosh J.M., Clementi F., Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22:2002;8785-8789